In a retrospective analysis of pretreated NEC G3, FOLFOX in second line after failure of standard PE chemotherapy showed activity in 30% of patients; the median PFS was more favorable for patients with Ki67 < 55% (6.2 months) versus Ki67 > 55% (3.6 months), respectively [11]. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.